IMMNOS Stock Overview
Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Immunovia AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr34.30 |
| 52 Week High | kr63.05 |
| 52 Week Low | kr30.28 |
| Beta | 1.41 |
| 1 Month Change | 0% |
| 3 Month Change | -4.08% |
| 1 Year Change | -44.68% |
| 3 Year Change | -79.87% |
| 5 Year Change | n/a |
| Change since IPO | -77.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| IMMNOS | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.7% | 1.3% |
| 1Y | -44.7% | -9.7% | 6.1% |
Return vs Industry: IMMNOS underperformed the UK Medical Equipment industry which returned -7.4% over the past year.
Return vs Market: IMMNOS underperformed the UK Market which returned -2.4% over the past year.
Price Volatility
| IMMNOS volatility | |
|---|---|
| IMMNOS Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: IMMNOS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IMMNOS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 64 | Philipp Mathieu | www.immunovia.com |
Immunovia AB (publ), a diagnostic company, develops and commercializes blood tests in Sweden and internationally. The company’s product includes IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. It also develops research projects for lung cancer.
Immunovia AB (publ) Fundamentals Summary
| IMMNOS fundamental statistics | |
|---|---|
| Market cap | kr551.76m |
| Earnings (TTM) | -kr147.90m |
| Revenue (TTM) | kr949.00k |
581.4x
P/S Ratio-3.7x
P/E RatioIs IMMNOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMMNOS income statement (TTM) | |
|---|---|
| Revenue | kr949.00k |
| Cost of Revenue | kr4.15m |
| Gross Profit | -kr3.20m |
| Other Expenses | kr144.70m |
| Earnings | -kr147.90m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 09, 2023
| Earnings per share (EPS) | -6.54 |
| Gross Margin | -336.78% |
| Net Profit Margin | -15,584.62% |
| Debt/Equity Ratio | 0% |
How did IMMNOS perform over the long term?
See historical performance and comparison